Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all ...

Absci Corp. ( (ABSI) ) has released its Q3 earnings. Here is a breakdown of the information Absci Corp. presented to its investors. Absci ...

Absci Corporation (ABSI) delivered earnings and revenue surprises of -26.32% and 4.01%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

In a report released today, Daniel Arias from Stifel Nicolaus maintained a Hold rating on AbSci (ABSI – Research Report), with a price ...

Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel antibody ...

and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended ...

USA News Group News Commentary – A recent World Economic Forum report highlights AI's potential to ease the strain on healthcare systems worldwide, noting Mayo Clinic’s ...

The popular fast-food restaurant operator faces an uphill battle.

It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug ...

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-based drug for cancer.